menu
    • menu

    Find Itraconazole manufacturers, exporters & distributors on PharmaCompass

    NEW Prospects: 28
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    94

    API Suppliers

    14

    USDMF

    17

    CEP/COS

    5

    JDMF

    13

    EU WC

    19

    KDMF

    16

    NDC API

    0

    VMF

    51

    Listed Suppliers

    31INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    2

    EDQM

    1

    USP

    0

    JP

    12

    Others

    FINISHED DOSAGE FORMULATIONS

    233

    FDF Dossiers

    20

    FDA Orange Book

    89

    Europe

    5

    Canada

    3

    Australia

    16

    South Africa

    100

    Listed Dossiers

    28PROSPECTS

    42DRUGS IN DEVELOPMENT

    FDF DossiersDRUG PRODUCT COMPOSITIONS

    202RELATED EXCIPIENT COMPANIES

    328EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    6

    US Patents

    0

    US Exclusivities

    3

    Health Canada Patents

    GLOBAL SALES INFORMATION

    US Medicaid

    10,466,751

    Annual Reports

    NA

    Regulatory FDF Prices

    MARKET PLACE

    47

    API

    7

    FDF

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    37

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Sporanox, 84625-61-6, Oriconazole, Itrizole (tn), Sporanox (tn), Itcz
    Molecular Formula
    C35H38Cl2N8O4
    Molecular Weight
    705.6  g/mol
    InChI Key
    VHVPQPYKVGDNFY-ZPGVKDDISA-N
    FDA UNII
    304NUG5GF4
    Itraconazole
    A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.
    Itraconazole is an Azole Antifungal. The mechanism of action of itraconazole is as a Cytochrome P450 3A4 Inhibitor, and P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
    1 2D Structure

    Itraconazole

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
    2.1.2 InChI
    InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
    2.1.3 InChI Key
    VHVPQPYKVGDNFY-ZPGVKDDISA-N
    2.1.4 Canonical SMILES
    CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
    2.1.5 Isomeric SMILES
    CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl
    2.2 Other Identifiers
    2.2.1 UNII
    304NUG5GF4
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Orungal

    2. R 51211

    3. R-51211

    4. R51211

    5. Sporanox

    2.3.2 Depositor-Supplied Synonyms

    1. Sporanox

    2. 84625-61-6

    3. Oriconazole

    4. Itrizole (tn)

    5. Sporanox (tn)

    6. Itcz

    7. Itrizole

    8. Itraconazol

    9. Orungal

    10. Sporonox

    11. Itraconazole (sporanox)

    12. 2-butan-2-yl-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one

    13. 873066-43-4

    14. R-51211

    15. Itraconazol [spanish]

    16. Itraconazolum [latin]

    17. Triasporin

    18. Candistat

    19. Canditral

    20. Itralek

    21. Sempera

    22. Sporamelt

    23. Traconal

    24. Chembl22587

    25. Itrac

    26. Cis-itraconazole

    27. Chebi:6076

    28. Spherazole Cr

    29. Spherazole Ir

    30. R51211

    31. Nsc-759239

    32. Itz

    33. Dsstox_cid_3180

    34. Dsstox_rid_76908

    35. (2r,4s)-itraconazole (mixture Of Diastereomers)

    36. Dsstox_gsid_23180

    37. Fungitraxx

    38. Cladosal 100

    39. 2-(butan-2-yl)-4-{4-[4-(4-{[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3h-1,2,4-triazol-3-one

    40. 4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one

    41. Cas-84625-61-6

    42. 304nug5gf4

    43. Intraconazole

    44. Itraconazolo

    45. Sporanox(tm)

    46. Ncgc00018268-03

    47. 3h-1,2,4-triazol-3-one, 4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)-

    48. 4-(4-{4-[4-({[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3h-1,2,4-triazol-3-one

    49. 84604-65-9

    50. Itraconazole & Nyotran

    51. R 51,211

    52. Itraconazole [mi]

    53. Itraconazole [inn]

    54. Itraconazole [jan]

    55. Itraconazole [inci]

    56. Itraconazole [usan]

    57. Itraconazole (jp17/usp)

    58. Itraconazole [vandf]

    59. Schembl23934

    60. Itraconazole [mart.]

    61. Mls006011958

    62. Itraconazole [usp-rs]

    63. Itraconazole [who-dd]

    64. Amy922

    65. Dtxsid3023180

    66. Gtpl11426

    67. Itraconazole [green Book]

    68. Itraconazole [ep Impurity]

    69. Itraconazole [orange Book]

    70. Pharmakon1600-01505756

    71. Itraconazole [ep Monograph]

    72. 4-(4-(4-(4-((2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3h-1,2,4-triazol-3-one

    73. Itraconazole [usp Monograph]

    74. Tox21_110854

    75. Ac-542

    76. Bdbm50127138

    77. Nsc759239

    78. S2476

    79. Akos015842738

    80. Akos015961385

    81. Tox21_110854_1

    82. Ccg-270391

    83. Db01167

    84. Ks-1268

    85. Ncgc00274068-01

    86. Ncgc00274068-02

    87. Ncgc00274068-07

    88. 1-(butan-2-yl)-4-{4-[4-(4-{[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1h-1,2,4-triazol-5-one

    89. 4-(4-(4-(4-(((2r,4s)-2-((1h-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3h-1,2,4-triazol-3-one

    90. Hy-17514

    91. Smr001827898

    92. Itraconazole & Nyotran(liposomal Nystatin)

    93. Sbi-0206914.p001

    94. Itraconazole (ema Epar: Veterinary)

    95. Sw219756-1

    96. Itraconazole 2.0 Mg/ml In Dimethyl Sulfoxide

    97. D00350

    98. Suba-itraconazole Component Itraconazole

    99. Ab01274818-01

    100. Ab01274818_02

    101. Ab01274818_03

    102. A933954

    103. Itraconazole Component Of Suba-itraconazole

    104. Q411229

    105. Brd-a23067620-001-01-7

    106. (+/-)-1-sec-butyl-4-(p-(4-(p-(((2r*,4s*)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-.delta.(sup 2)-1,2,4-triazolin-5-one

    107. 3h-1,2,4-triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)

    108. 4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1h-1,2,4-triazole-1-ylmethyl)-1,3-dioxolane-4-yl]methoxy]phenyl]piperazino]phenyl]-2-(1-methylpropyl)-4h-1,2,4-triazole-3(2h)-one

    2.4 Create Date
    2005-06-24
    3 Chemical and Physical Properties
    Molecular Weight 705.6 g/mol
    Molecular Formula C35H38Cl2N8O4
    XLogP35.7
    Hydrogen Bond Donor Count0
    Hydrogen Bond Acceptor Count9
    Rotatable Bond Count11
    Exact Mass704.2393071 g/mol
    Monoisotopic Mass704.2393071 g/mol
    Topological Polar Surface Area101 Ų
    Heavy Atom Count49
    Formal Charge0
    Complexity1120
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 4  
    Drug NameItraconazole
    PubMed HealthItraconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelSPORANOX is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the followi...
    Active IngredientItraconazole
    Dosage FormCapsule
    RouteOral
    Strength100mg
    Market StatusPrescription
    CompanyMylan Pharms; Sandoz

    2 of 4  
    Drug NameSporanox
    PubMed HealthItraconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelSPORANOX is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the followi...
    Active IngredientItraconazole
    Dosage FormCapsule; Solution
    Routeoral; Oral
    Strength10mg/ml; 100mg
    Market StatusPrescription
    CompanyJanssen Pharms; Janssen Pharma

    3 of 4  
    Drug NameItraconazole
    PubMed HealthItraconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelSPORANOX is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the followi...
    Active IngredientItraconazole
    Dosage FormCapsule
    RouteOral
    Strength100mg
    Market StatusPrescription
    CompanyMylan Pharms; Sandoz

    4 of 4  
    Drug NameSporanox
    PubMed HealthItraconazole (By mouth)
    Drug ClassesAntifungal
    Drug LabelSPORANOX is the brand name for itraconazole, a synthetic triazole antifungal agent. Itraconazole is a 1:1:1:1 racemic mixture of four diastereomers (two enantiomeric pairs), each possessing three chiral centers. It may be represented by the followi...
    Active IngredientItraconazole
    Dosage FormCapsule; Solution
    Routeoral; Oral
    Strength10mg/ml; 100mg
    Market StatusPrescription
    CompanyJanssen Pharms; Janssen Pharma

    4.2 Therapeutic Uses

    Antifungal Agents; Antiprotozoal Agents

    National Library of Medicine's Medical Subject Headings online file (MeSH, 2009)

    Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary; Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium) and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). /Included in US product label/

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    4.3 Drug Warning

    /BOXED WARNING/ Congestive Heart Failure, Cardiac Effects: Itraconazole capsules should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF. If signs or symptoms of congestive heart failure occur during administration of itraconazole capsules, discontinue administration. When itraconazole was administered intravenously to dogs and healthy human volunteers, negative inotropic effects were seen.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (Updated: June 2014). Available from, as of April 24, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d343050e-00bb-440c-a24b-7cd18c97e184

    /BOXED WARNING/ Drug Interactions: Coadministration of the following drugs are contraindicated with itraconazole capsules: methadone, disopyramide, dofetilide, dronedarone, quinidine, ergot alkaloids (such as dihydroergotamine, ergometrine (ergonovine), ergotamine, methylergometrine (methylergonovine)), irinotecan, lurasidone, oral midazolam, pimozide, triazolam, felodipine, nisoldipine, ranolazine, eplerenone, cisapride, lovastatin, simvastatin and, in subjects with renal or hepatic impairment, colchicine. Coadministration with itraconazole can cause elevated plasma concentrations of these drugs and may increase or prolong both the pharmacologic effects and/or adverse reactions to these drugs. For example, increased plasma concentrations of some of these drugs can lead to QT prolongation and ventricular tachyarrhythmias including occurrences of torsades de pointes, a potentially fatal arrhythmia.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (Updated: June 2014). Available from, as of April 24, 2015: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d343050e-00bb-440c-a24b-7cd18c97e184

    Itraconazole is contraindicated in patients with known hypersensitivity to the drug or any ingredient in the formulation. Although information concerning cross-sensitivity between itraconazole and other triazole or imidazole antifungal agents is not available, the manufacturer states that itraconazole should be used with caution in individuals hypersensitive to other azoles.

    American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 531

    Adverse GI effects have been reported in about 1-11% of patients receiving IV or oral itraconazole for the treatment of systemic fungal infections or oropharyngeal or esophageal candidiasis or for empiric anti-fungal therapy. These adverse GI effects usually are transient and respond to symptomatic treatment without alteration of itraconazole therapy; however, reduction of dosage or discontinuance of the drug occasionally may be required.

    American Society of Health System Pharmacists; AHFS Drug Information 2010. Bethesda, MD. (2010), p. 530

    For more Drug Warnings (Complete) data for Itraconazole (27 total), please visit the HSDB record page.

    4.4 Drug Indication

    For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

    FDA Label

    For the treatment of aspergillosis and candidiasis in companion birds

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans.

    5.2 MeSH Pharmacological Classification

    14-alpha Demethylase Inhibitors

    Compounds that specifically inhibit STEROL 14-DEMETHYLASE. A variety of azole-derived ANTIFUNGAL AGENTS act through this mechanism. (See all compounds classified as 14-alpha Demethylase Inhibitors.)

    Antifungal Agents

    Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)

    Cytochrome P-450 CYP3A Inhibitors

    Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP3A. (See all compounds classified as Cytochrome P-450 CYP3A Inhibitors.)

    5.3 FDA Pharmacological Classification
    5.3.1 Active Moiety
    ITRACONAZOLE
    5.3.2 FDA UNII
    304NUG5GF4
    5.3.3 Pharmacological Classes
    Azoles [CS]; Breast Cancer Resistance Protein Inhibitors [MoA]; Cytochrome P450 3A4 Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Azole Antifungal [EPC]
    5.4 ATC Code

    QJ02AC02

    J02AC02

    S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355

    J - Antiinfectives for systemic use

    J02 - Antimycotics for systemic use

    J02A - Antimycotics for systemic use

    J02AC - Triazole and tetrazole derivatives

    J02AC02 - Itraconazole

    5.5 Absorption, Distribution and Excretion

    Absorption

    The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.

    Route of Elimination

    Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.

    Volume of Distribution

    796 185 L

    Clearance

    381 +/- 95 mL/minute [IV administration]

    The pharmacokinetics of itraconazole after intravenous administration and its absolute oral bioavailability from an oral solution were studied in a randomized crossover study in 6 healthy male volunteers. The observed absolute oral bioavailability of itraconazole was 55%.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    The oral bioavailability of itraconazole is maximal when itraconazole capsules are taken with a full meal. The pharmacokinetics of itraconazole were studied in 6 healthy male volunteers who received, in a crossover design, single 100 mg doses of itraconazole as a polyethylene glycol capsule, with or without a full meal. The same 6 volunteers also received 50 mg or 200 mg with a full meal in a crossover design. In this study, only itraconazole plasma concentrations were measured. The respective pharmacokinetic parameters for itraconazole are presented in the table /provided/.

    Table: Oral Bioavailability of Itraconazole (Itraconazole capsules): [Table#7591]

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    [Table#7591]

    Steady-state concentrations were reached within 15 days following oral doses of 50 mg to 400 mg daily. Values given in the table below are data at steady-state from a pharmacokinetics study in which 27 healthy male volunteers took 200 mg itraconazole capsules b.i.d. (with a full meal) for 15 days [Table#7592]

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    [Table#7592]

    Thirty healthy men received single 200 mg doses of itraconazole capsules under fasted conditions either 1) with water; 2) with water, after ranitidine 150 mg b.i.d. for 3 days; or 3) with cola, after ranitidine 150 mg b.i.d. for 3 days. When itraconazole capsules were administered after ranitidine pretreatment, itraconazole was absorbed to a lesser extent than when itraconazole capsules were administered alone, with decreases in AUC0-24 and Cmax of 39% +/- 37% and 42% +/- 39%, respectively. When itraconazole capsules were administered with cola after ranitidine pretreatment, itraconazole absorption was comparable to that observed when itraconazole capsules were administered alone.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    For more Absorption, Distribution and Excretion (Complete) data for Itraconazole (11 total), please visit the HSDB record page.

    5.6 Metabolism/Metabolites

    Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.

    Itraconazole is metabolized predominantly by the cytochrome P450 3A4 isoenzyme system (CYP3A4), resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Results of a pharmacokinetics study suggest that itraconazole may undergo saturable metabolism with multiple dosing.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    Itraconazole (ITZ) is metabolized in vitro to three inhibitory metabolites: hydroxy-itraconazole (OH-ITZ), keto-itraconazole (keto-ITZ), and N-desalkyl-itraconazole (ND-ITZ). The goal of this study was to determine the contribution of these metabolites to drug-drug interactions caused by ITZ. Six healthy volunteers received 100 mg ITZ orally for 7 days, and pharmacokinetic analysis was conducted at days 1 and 7 of the study. The extent of CYP3A4 inhibition by ITZ and its metabolites was predicted using this data. ITZ, OH-ITZ, keto-ITZ, and ND-ITZ were detected in plasma samples of all volunteers. A 3.9-fold decrease in the hepatic intrinsic clearance of a CYP3A4 substrate was predicted using the average unbound steady-state concentrations (C(ss,ave,u)) and liver microsomal inhibition constants for ITZ, OH-ITZ, keto-ITZ, and ND-ITZ. Accounting for circulating metabolites of ITZ significantly improved the in vitro to in vivo extrapolation of CYP3A4 inhibition compared to a consideration of ITZ exposure alone.

    PMID:17495874 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488349 Templeton IE et al; Clin Pharmacol Ther 83 (1): 77-85 (2008)

    5.7 Biological Half-Life

    21 hours

    5.8 Mechanism of Action

    Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

    In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.

    US Natl Inst Health; DailyMed. Current Medication Information for Itraconazole (itraconazole) capsule (February 2010). Available from, as of September 27, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16279

    API SUPPLIERS

    read-more
    read-more

    01

    LGM Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    Interphex
    Booth #2158
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    LGM Pharma CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Metrochem API Private Limited

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Japan
    Booth #1J-48
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WCarrow-down
    ✖

    Date of Issue : 2024-04-03

    Valid Till : 2027-01-21

    Written Confirmation Number : WC-0493

    Address of the Firm :

    NDC KDMF VMF Others AUDIT arrow-down
    Metrochem

    03

    Jai Radhe Sales

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothJai Radhe Sales is your partner for all your sourcing needs.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Jai Radhe Sales

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Tenatra Exports

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothTenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Tenatra

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Zeon Pharma Industries India Pvt L...

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothZeon Pharma is a manufacturer and supplier of APIs & Intermediates.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Zeon Pharma Industries India Pvt Ltd

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Zeal Medipharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothDelivering Quality APIs, Drug Intermediates, and Specialty Chemicals to Over 50 Countries Across the Globe.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Willow Birch Pharma

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothWillow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Contact Supplier Contact Supplier
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Cerata Pharmaceuticals LLP

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI Middle East
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothCerata Pharmaceuticals LLP: WHO-GMP Certified Leading Manufacturer & Exporter of Steroid-Hormone & Peptide APIs From India.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Murli Krishna Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    ICMD China
    Not Confirmed
    arrow

    Murli Krishna Pharma

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 27410

    Submission : 2013-08-01

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Grace

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    ICMD China
    Not Confirmed
    arrow

    Grace

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    ICMD China
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2018-02-08

    Pay. Date : 2017-12-28

    DMF Number : 12697

    Submission : 1997-10-16

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 1999-196 - Rev 04

    Issue Date : 2021-07-29

    Type : Chemical

    Substance Number : 1335

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 22568-1108

    Start Marketing Date : 2021-06-01

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-moreread-more

    W. R. GRACE & CO.-CONN. Columbia US

    Contact Supplier
    • FDA
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 1999-196 - Rev 04
    Valid
    Chemical
    2021-07-29
    1335
    blank

    01

    W. R. GRACE & CO.-CONN. Columbia US

    U.S.A
    ICMD China
    Not Confirmed
    arrow

    W. R. GRACE & CO.-CONN. Columbia US

    U.S.A
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R1-CEP 1999-196 - Rev 04

    Status : Valid

    Issue Date : 2021-07-29

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    HETERO DRUGS LIMITED Hyderabad IN

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2005-289 - Rev 01
    Withdrawn by Holder
    Chemical
    2017-09-04
    2018-05-24
    1335
    blank

    02

    HETERO DRUGS LIMITED Hyderabad IN

    India
    ICMD China
    Not Confirmed
    arrow

    HETERO DRUGS LIMITED Hyderabad IN

    India
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R1-CEP 2005-289 - Rev 01

    Status : Withdrawn by Holder

    Issue Date : 2017-09-04

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    JANSSEN PHARMACEUTICA NV Beerse BE

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole, Method 1

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 1999-092 - Rev 07
    Valid
    Chemical
    2017-02-07
    1335
    blank

    03

    JANSSEN PHARMACEUTICA NV Beerse BE

    U.S.A
    ICMD China
    Not Confirmed
    arrow

    JANSSEN PHARMACEUTICA NV Beerse BE

    U.S.A
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole, Method 1

    Certificate Number : R1-CEP 1999-092 - Rev 07

    Status : Valid

    Issue Date : 2017-02-07

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    JANSSEN PHARMACEUTICA NV Beerse BE

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole, Method 2 (alternative synthesis)

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2001-140 - Rev 05
    Valid
    Chemical
    2016-01-22
    1335
    blank

    04

    JANSSEN PHARMACEUTICA NV Beerse BE

    U.S.A
    ICMD China
    Not Confirmed
    arrow

    Janssen Pharmaceutical Ltd County C...

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R0-CEP 2001-150 - Rev 01
    Withdrawn by Holder
    Chemical
    2004-11-16
    2005-09-20
    1335
    blank

    05

    Janssen Pharmaceutical Ltd County C...

    U.S.A
    ICMD China
    Not Confirmed
    arrow

    Janssen Pharmaceutical Ltd County C...

    U.S.A
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag U.S.A
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R0-CEP 2001-150 - Rev 01

    Status : Withdrawn by Holder

    Issue Date : 2004-11-16

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Choongwae Pharma Corporation Seoul

    Contact Supplier
    • FDA
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R0-CEP 2003-039 - Rev 00
    Expired
    Chemical
    2004-10-12
    2009-10-12
    1335
    blank

    06

    Choongwae Pharma Corporation Seoul

    South Korea
    ICMD China
    Not Confirmed
    arrow

    Choongwae Pharma Corporation Seoul

    South Korea
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag South Korea
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R0-CEP 2003-039 - Rev 00

    Status : Expired

    Issue Date : 2004-10-12

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    QUIMICA SINTETICA S.A. Alcala De He...

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole, Process II

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2016-006 - Rev 00
    Valid
    Chemical
    2021-04-16
    1335
    blank

    07

    QUIMICA SINTETICA S.A. Alcala De He...

    Spain
    ICMD China
    Not Confirmed
    arrow

    QUIMICA SINTETICA S.A. Alcala De He...

    Contact Supplier
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 1999-139 - Rev 03
    Withdrawn by Holder
    Chemical
    2016-12-09
    2025-02-18
    1335
    blank

    08

    QUIMICA SINTETICA S.A. Alcala De He...

    Spain
    ICMD China
    Not Confirmed
    arrow

    QUIMICA SINTETICA S.A. Alcala De He...

    Spain
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag Spain
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R1-CEP 1999-139 - Rev 03

    Status : Withdrawn by Holder

    Issue Date : 2016-12-09

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    SMS PHARMACEUTICALS LIMITED Hyderab...

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole, Bachupally site

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R1-CEP 2012-403 - Rev 01
    Valid
    Chemical
    2019-09-16
    1335
    blank

    09

    SMS PHARMACEUTICALS LIMITED Hyderab...

    India
    ICMD China
    Not Confirmed
    arrow

    SMS PHARMACEUTICALS LIMITED Hyderab...

    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    R0-CEP 2005-061 - Rev 02
    Expired
    Chemical
    2009-09-21
    2014-01-14
    1335
    blank

    10

    SMS PHARMACEUTICALS LIMITED Hyderab...

    India
    ICMD China
    Not Confirmed
    arrow

    SMS PHARMACEUTICALS LIMITED Hyderab...

    India
    arrow
    ICMD China
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
    Post an Enquiry Post an Enquiry
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Itraconazole

    Certificate Number : R0-CEP 2005-061 - Rev 02

    Status : Expired

    Issue Date : 2009-09-21

    Type : Chemical

    Substance Number : 1335

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    DRUG PRODUCT COMPOSITIONS

    Do you need Business Intel? Ask us

    DOSAGE - CAPSULE;ORAL - 100MG

    USFDA APPLICATION NUMBER - 20083

    read-more

    DOSAGE - TABLET;ORAL - 200MG

    USFDA APPLICATION NUMBER - 22484

    read-more

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Coating Systems & Additives

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Controlled & Modified Release

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Granulation

    read-more
    read-more

    Film Formers & Plasticizers

    read-more
    read-more

    Solubilizers

    read-more
    read-more

    Lubricants & Glidants

    read-more
    read-more

    Topical

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Empty Capsules

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Emulsifying Agents

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Vegetarian Capsules

    read-more
    read-more

    Surfactant & Foaming Agents

    read-more
    read-more

    Coloring Agents

    read-more
    read-more

    Rheology Modifiers

    read-more
    read-more

    Soft Gelatin

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    USP

    read-more
    read-more

    ANALYTICAL

    Upload your methods for free, ask us

    ABOUT THIS PAGE

    Looking for 84625-61-6 / Itraconazole API manufacturers, exporters & distributors?

    Itraconazole manufacturers, exporters & distributors 1

    11

    PharmaCompass offers a list of Itraconazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Itraconazole manufacturer or Itraconazole supplier for your needs.

    Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Itraconazole manufacturer or Itraconazole supplier.

    PharmaCompass also assists you with knowing the Itraconazole API Price utilized in the formulation of products. Itraconazole API Price is not always fixed or binding as the Itraconazole Price is obtained through a variety of data sources. The Itraconazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

    API | Excipient name

    Itraconazole

    Synonyms

    Sporanox, 84625-61-6, Oriconazole, Itrizole (tn), Sporanox (tn), Itcz

    Cas Number

    84625-61-6

    Unique Ingredient Identifier (UNII)

    304NUG5GF4

    About Itraconazole

    A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.

    Itraconazolum Manufacturers

    A Itraconazolum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Itraconazolum, including repackagers and relabelers. The FDA regulates Itraconazolum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Itraconazolum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Itraconazolum manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Itraconazolum Suppliers

    A Itraconazolum supplier is an individual or a company that provides Itraconazolum active pharmaceutical ingredient (API) or Itraconazolum finished formulations upon request. The Itraconazolum suppliers may include Itraconazolum API manufacturers, exporters, distributors and traders.

    click here to find a list of Itraconazolum suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Itraconazolum USDMF

    A Itraconazolum DMF (Drug Master File) is a document detailing the whole manufacturing process of Itraconazolum active pharmaceutical ingredient (API) in detail. Different forms of Itraconazolum DMFs exist exist since differing nations have different regulations, such as Itraconazolum USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Itraconazolum DMF submitted to regulatory agencies in the US is known as a USDMF. Itraconazolum USDMF includes data on Itraconazolum's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Itraconazolum USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Itraconazolum suppliers with USDMF on PharmaCompass.

    Itraconazolum JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Itraconazolum Drug Master File in Japan (Itraconazolum JDMF) empowers Itraconazolum API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Itraconazolum JDMF during the approval evaluation for pharmaceutical products. At the time of Itraconazolum JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Itraconazolum suppliers with JDMF on PharmaCompass.

    Itraconazolum KDMF

    In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

    Pharmaceutical companies submit a Itraconazolum Drug Master File in Korea (Itraconazolum KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Itraconazolum. The MFDS reviews the Itraconazolum KDMF as part of the drug registration process and uses the information provided in the Itraconazolum KDMF to evaluate the safety and efficacy of the drug.

    After submitting a Itraconazolum KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Itraconazolum API can apply through the Korea Drug Master File (KDMF).

    click here to find a list of Itraconazolum suppliers with KDMF on PharmaCompass.

    Itraconazolum CEP

    A Itraconazolum CEP of the European Pharmacopoeia monograph is often referred to as a Itraconazolum Certificate of Suitability (COS). The purpose of a Itraconazolum CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Itraconazolum EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Itraconazolum to their clients by showing that a Itraconazolum CEP has been issued for it. The manufacturer submits a Itraconazolum CEP (COS) as part of the market authorization procedure, and it takes on the role of a Itraconazolum CEP holder for the record. Additionally, the data presented in the Itraconazolum CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Itraconazolum DMF.

    A Itraconazolum CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Itraconazolum CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

    click here to find a list of Itraconazolum suppliers with CEP (COS) on PharmaCompass.

    Itraconazolum WC

    A Itraconazolum written confirmation (Itraconazolum WC) is an official document issued by a regulatory agency to a Itraconazolum manufacturer, verifying that the manufacturing facility of a Itraconazolum active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Itraconazolum APIs or Itraconazolum finished pharmaceutical products to another nation, regulatory agencies frequently require a Itraconazolum WC (written confirmation) as part of the regulatory process.

    click here to find a list of Itraconazolum suppliers with Written Confirmation (WC) on PharmaCompass.

    Itraconazolum NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Itraconazolum as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Itraconazolum API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Itraconazolum as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Itraconazolum and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Itraconazolum NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Itraconazolum suppliers with NDC on PharmaCompass.

    Itraconazolum GMP

    Itraconazolum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Itraconazolum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Itraconazolum GMP manufacturer or Itraconazolum GMP API supplier for your needs.

    Itraconazolum CoA

    A Itraconazolum CoA (Certificate of Analysis) is a formal document that attests to Itraconazolum's compliance with Itraconazolum specifications and serves as a tool for batch-level quality control.

    Itraconazolum CoA mostly includes findings from lab analyses of a specific batch. For each Itraconazolum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Itraconazolum may be tested according to a variety of international standards, such as European Pharmacopoeia (Itraconazolum EP), Itraconazolum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Itraconazolum USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search